Nationwide Fund Advisors boosted its holdings in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 240.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,691 shares of the specialty pharmaceutical company’s stock after purchasing an additional 171,341 shares during the period. Nationwide Fund Advisors owned about 0.48% of Supernus Pharmaceuticals worth $9,708,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Alpha Cubed Investments LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth about $254,000. LS Investment Advisors LLC raised its stake in Supernus Pharmaceuticals by 30.9% in the 3rd quarter. LS Investment Advisors LLC now owns 9,148 shares of the specialty pharmaceutical company’s stock worth $366,000 after purchasing an additional 2,162 shares in the last quarter. Winslow Evans & Crocker Inc. acquired a new stake in Supernus Pharmaceuticals in the 3rd quarter worth about $273,000. Ashford Capital Management Inc. raised its stake in Supernus Pharmaceuticals by 1.5% in the 2nd quarter. Ashford Capital Management Inc. now owns 756,140 shares of the specialty pharmaceutical company’s stock worth $32,590,000 after purchasing an additional 11,506 shares in the last quarter. Finally, U S Global Investors Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $1,914,000. 98.22% of the stock is owned by institutional investors and hedge funds.
SUPN has been the topic of several research reports. Piper Jaffray Companies reaffirmed a “hold” rating and set a $41.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. FBR & Co began coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 target price on the stock. SunTrust Banks reaffirmed a “buy” rating and issued a $61.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, November 3rd. Finally, Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and an average price target of $50.00.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. The firm’s revenue for the quarter was up 41.5% compared to the same quarter last year. analysts expect that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Nationwide Fund Advisors Purchases 171,341 Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN)” was first published by Week Herald and is owned by of Week Herald. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://weekherald.com/2017/12/30/supernus-pharmaceuticals-inc-supn-holdings-lifted-by-nationwide-fund-advisors.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.